Exploring TPC2 as target for age-dependent macular degeneration therapy
(P12)
Subject Area
Pharmacology
Term
since 2014
Project identifier
Deutsche Forschungsgemeinschaft (DFG) - Project number 239283807
The endolysosomal two-pore channel 2 (TPC2) plays a key role in neovascularization and immune activation in the mouse model of laser-induced choroidal neovascularization (CNV) of age-related macular degeneration (AMD). Here, we will investigate the potential involvement of TPC2 in proliferative diabetic retinopathy. In addition, we will examine the effects of direct TPC2 activation on retinal neovascularization and immune activation. Finally, we will develop a gene therapy approach based on CRISPR/Cas9-mediated inactivation of Tpc2. Overall, the proposal aims at defining the therapeutic impact of TPC2 for the future treatment of AMD and related retinal disorders.
DFG Programme
CRC/Transregios
